Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MDX-1100 in active ulcerative colitis
2007-002544-25Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing MDX-1100 with Placebo (2 arms). Primary endpoints: Clinical response rate at Day 57 and Tolerability and safety. Started Jan 2008; status: completed.
02
Drugs
eldelumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2007-002544-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002544-25.